AU2008267151B2 - Composition and method for treatment of autoimmune disease - Google Patents

Composition and method for treatment of autoimmune disease Download PDF

Info

Publication number
AU2008267151B2
AU2008267151B2 AU2008267151A AU2008267151A AU2008267151B2 AU 2008267151 B2 AU2008267151 B2 AU 2008267151B2 AU 2008267151 A AU2008267151 A AU 2008267151A AU 2008267151 A AU2008267151 A AU 2008267151A AU 2008267151 B2 AU2008267151 B2 AU 2008267151B2
Authority
AU
Australia
Prior art keywords
tlr2
antibody
receptor
toll
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008267151A
Other languages
English (en)
Other versions
AU2008267151A1 (en
Inventor
Mark Heffernan
Brian Keogh
Christopher Locher
Peter Mcguirk
Luke O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuramedy Co Ltd
Original Assignee
Neuramedy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuramedy Co Ltd filed Critical Neuramedy Co Ltd
Publication of AU2008267151A1 publication Critical patent/AU2008267151A1/en
Application granted granted Critical
Publication of AU2008267151B2 publication Critical patent/AU2008267151B2/en
Assigned to NEURAMEDY CO., LTD. reassignment NEURAMEDY CO., LTD. Request for Assignment Assignors: OPSONA THERAPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
AU2008267151A 2007-06-28 2008-06-27 Composition and method for treatment of autoimmune disease Active AU2008267151B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IE20070468 2007-06-28
IE2007/0468 2007-06-28
US3837208P 2008-03-20 2008-03-20
US61/038,372 2008-03-20
IE20080209 2008-03-20
IE2008/0209 2008-03-20
PCT/EP2008/058339 WO2009000929A2 (en) 2007-06-28 2008-06-27 Composition and method for treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
AU2008267151A1 AU2008267151A1 (en) 2008-12-31
AU2008267151B2 true AU2008267151B2 (en) 2014-02-20

Family

ID=39758798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008267151A Active AU2008267151B2 (en) 2007-06-28 2008-06-27 Composition and method for treatment of autoimmune disease

Country Status (7)

Country Link
US (1) US8580255B2 (https=)
EP (1) EP2170392A2 (https=)
JP (1) JP5554703B2 (https=)
CN (1) CN101808662A (https=)
AU (1) AU2008267151B2 (https=)
CA (1) CA2691784C (https=)
WO (1) WO2009000929A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278817A1 (en) * 2007-07-05 2010-11-04 Opsona Therapeutics Ltd. Compounds and methods for the treatment of renal disease
US9981018B2 (en) 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
WO2011156451A2 (en) * 2010-06-08 2011-12-15 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
WO2012011100A1 (en) * 2010-07-19 2012-01-26 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases
CN103562387A (zh) 2011-03-03 2014-02-05 夸克医药公司 Toll样受体途径的寡核苷酸调剂
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2970428A4 (en) * 2013-03-15 2016-08-31 Univ Florida COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE PROTEINOPATHIES
WO2016154586A1 (en) * 2015-03-26 2016-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Toll-like receptor 2 ligands and methods of making and using thereof
CN107847657A (zh) * 2015-06-15 2018-03-27 生命治疗有限公司 用于诱导抗炎反应的组合物和方法
EP3735129B1 (en) 2018-01-02 2025-02-05 Rush University Medical Center Compositions and methods for treating neurological and other disorders
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077471A2 (en) * 2004-12-10 2006-07-27 Novimmune S.A. Combining therapies targeting multiple toll-like receptors and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
US7388080B2 (en) * 2003-08-20 2008-06-17 University Of Massachusetts Selective inhibition of toll-like receptor-2
ATE510853T1 (de) * 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
WO2005039504A2 (en) * 2003-10-24 2005-05-06 Eisai Co., Ltd. Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2005079419A2 (en) * 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
CA2596509A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
EP2139916A1 (en) 2007-04-26 2010-01-06 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077471A2 (en) * 2004-12-10 2006-07-27 Novimmune S.A. Combining therapies targeting multiple toll-like receptors and use thereof

Also Published As

Publication number Publication date
EP2170392A2 (en) 2010-04-07
AU2008267151A1 (en) 2008-12-31
CA2691784C (en) 2016-11-01
WO2009000929A3 (en) 2009-02-26
US20100247527A1 (en) 2010-09-30
CA2691784A1 (en) 2008-12-31
JP2010531846A (ja) 2010-09-30
JP5554703B2 (ja) 2014-07-23
CN101808662A (zh) 2010-08-18
WO2009000929A2 (en) 2008-12-31
US8580255B2 (en) 2013-11-12

Similar Documents

Publication Publication Date Title
AU2008267151B2 (en) Composition and method for treatment of autoimmune disease
JP7538721B2 (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
JP4938957B2 (ja) Ｃｄ３０またはｃｄ３０ｌのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法
TWI589587B (zh) 中和性抗－ｃｃｌ２０抗體
JP6671069B2 (ja) 炎症性疾患の予防又は治療剤
JP2008532936A (ja) インターロイキン−１７ｆ抗体及び他のｉｌ−１７ｆシグナル伝達拮抗物質並びにそれらの使用
JP2025134864A (ja) 抗ケモカイン様受容体１ヒト化抗体及びその治療適用
US8414887B2 (en) Methods for suppressing Toll-like Receptor 4 (TLR4) function using TLR14 antagonists
US9234046B2 (en) Treatment of renal disease
EP2214692A2 (en) Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions
KR20230086809A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
CN101123983A (zh) 特定修饰对相关抗原的亲和力来调节抗体的特异性
EP2722342A1 (en) Methods and compositions for the treatment of pancreatic cancer
EP3548081B1 (en) Methods and compositions for the treatment of myelodysplastic syndrome
CN114901695A (zh) 抗gitr抗体及其用途
TW202202171A (zh) 使用ｉｌ－２０拮抗劑和免疫檢查點抑制劑之混合式治療
HK1199271B (en) Use of anti-cd83 agonist antibodies for treating autoimmune diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEURAMEDY CO., LTD.

Free format text: FORMER OWNER(S): OPSONA THERAPEUTICS LIMITED